Endpoints Capital is an Australian firm specializing in R&D financing for the life sciences industry. They provide innovative funding solutions, such as the Endpoints Accelerator Loan, which allows biotech companies to access their R&D tax incentives immediately rather than waiting up to 18 months. This funding model helps companies extend their R&D cash runway, optimize spending, and delay capital raisings that could dilute ownership. With a fast funding process, typically within 72 hours of receiving the required documents, Endpoints Capital ensures biotech firms can focus on achieving their clinical goals without financial delays.